IP Library Granted Patent US 9,056,060
Granted Patent B2
US 9,056,060 · App. 09/955,644 · Granted Jun 16, 2015

Non-reactive adhesive useful in transdermal drug delivery system

Inventors: Eric Silverberg (Clifton, NJ); Rama Chandran (Bridgewater, NJ); Paul Foreman (Somerville, NJ); Michael Philbin (Hopewell, NJ); Smita Shah (Edison, NJ)
Assignee: Henkel AG & Co. KGaA
A61K9/7053A61K9/7061A61L15/58C09J133/062
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,056,060
App. No.
09/955,644
Granted
Jun 16, 2015
Kind
B2
Abstract

An adhesive composition which lacks functional groups containing reactive hydrogen moieties and contains no post-polymerization chemical crosslinker finds use in transdermal drug delivery systems. The invention enables the administration of drugs containing a reactive functional group, which drugs have heretofore not been able to be administered by the transdermal route using conventional acrylic adhesives.

Claims (7)

1. A composition consisting of

an adhesive polymer prepared from a mixture of monomers consisting of:

about 45 wt %, based on the total monomer weight, of 2-ethyl hexyl acrylate, about 35 wt %, based on the total monomer weight, of methyl acrylate, and about 20 wt %, based on the total monomer weight, of t-octylacrylamide, dimethyl acrylamide, isopropyl acrylamide, or vinyl acetamide;

a therapeutic agent that is a non-salt; and

at least one ingredient selected from the group consisting of enhancer, plasticizer, tackifying agent, viscosity modifier, excipient, diluent, emollient, anti-irritant, opacifier, pigment, and preservative, wherein the composition is a transdermal composition.

2. The composition of claim 1 , wherein the mixture of monomers consists of 45 wt % of 2-ethylhexyl acrylate, 35 wt % of methyl acrylate and 20 wt % of t-octyl acrylamide.

3. The composition of claim 1 , wherein the therapeutic agent is fentanyl.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2010
From: NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION
To: HENKEL KGAA
Reel/Frame 024703/0842 →
CHANGE OF NAME Recorded Jul 19, 2010
From: HENKEL KGAA
To: HENKEL AG & CO. KGAA
Reel/Frame 024703/0960 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2002
From: SILVERBERG, ERIC; CHANDRAN, RAMA; FOREMAN, PAUL; PHILBIN, MICHAEL; SHAH, SMITA
To: NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION
Reel/Frame 012538/0798 →
Continuity (2)
Provisional Application 60234248 · Sep 19, 2000
Related Publication 20020077437A1 · Jun 20, 2002